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Abstract
Introduction: Spectroscopic and spectrometric analysis of biological samples is
regarded as quick, cost effective, easy to operate, and spectroscopic sample
preparation involves minimal sample preparation. Results: Techniques like
infrared (IR) spectroscopy, surface-enhanced laser desorption/ionization
(SELDI)-mass spectroscopy (MS), and matrix-assisted laser desorption/ioniza-
tion (MALDI) -MS could enable early diagnosis of cancer, disease monitoring,
and assessment of treatment responses allowing refinement, if required. Discus-
sion: Carrying out analytical testing within outpatient clinics would dramati-
cally cut the time spent by patients attending different appointments, at
different locations, save hospital time and resources but importantly would the-
oretically enable a reduction in mortality and morbidity. While the advantages
of such a prospect seem obvious, this review aims to evaluate the use of human
serum spectroscopic and spectrometric analysis as a diagnostic tool for brain
cancers, creating a platform for the future of cancer diagnostics.
Introduction
With nearly 9400 new cases of brain tumors diagnosed
each year in the UK and over half of them resulting in
death, the demand for a rapid, noninvasive diagnostic test
permitting early detection is as vital and evident as ever
(Cancer Research UK).
Brain tumors form when normal cells within the brain
mutate, grow uncontrollably and form a mass. Brain
tumors are stratified into increasing grades of malignancy
determined by how they are likely to grow, the likelihood
of reoccurrence, and the likely best treatment, highlighted
in Figure 1 (Wen and Kesari 2008). Gliomas occurring
from the glial cells within the brain and central nervous
system (CNS) (Hands et al. 2014) are the most common
primary brain tumor classified by World Health Organi-
sation (WHO) (Louis et al. 2007). Gliomas are often
diagnosed late, are hard to treat, and the prognosis is
poor. Generally, only 40% of patients with brain tumors
are alive more than 1 year after diagnosis (Cancer
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Research UK). Traditional treatment involves surgery,
radiation therapy, and chemotherapy but even with an
extensive treatment plan survival is poor as symptoms are
often diagnosed too late. The most common tumor types;
astrocytomas, ependymomas, and oligodendrogliomas
have very different outcomes.
Grade I and II astrocytomas are slow growing; often
grade I tumors can be completely removed through sur-
gery, producing a good outlook. Grade II tumors have
moderate survival rates, 40% of those diagnosed survive
for more than 10 years; nevertheless, they can develop
into higher grade, harder to treat tumors the longer they
go undiagnosed and untreated. Glioblastoma (GB), a
grade IV rapidly growing astrocytoma, often leads to
patients living for less than 1 year, only 6% survive for
more than 5 years (Hands et al. 2014). Identification and
analysis, within clinics, of characteristic biomarkers/
biosignatures present within an individual’s blood would
enable the early detection of grade II, III, and IV gliomas,
allowing for earlier treatment, leading to improved
patient mortality, morbidity, and quality of life (Cancer
Research UK; The Brain Tumour Charity).
Despite extensive therapeutic development resulting in a
variety of treatments, brain tumors still result in low
Cell of origin: Diﬀerenated Glial or Stem or Progenitor Cells 
Olig2 expression (100%) 
LOH 1p, 4q, 19q
EGFR overexpressed
PDGF/PDGFR overexpressed
Low-Grade Oligodendroglioma (5–10 years)*
(WHO Grade II)
P16Ink4a/P14ARF loss
RB mutated (~65%)
p53 mutated
PTEN loss
LOH 9p, 10q
CDK4/EGFR/MYC ampliﬁed
VEGF overexpressed
Anaplasc Oligodendroglioma (3–5 years) 
(WHO Grade III)
Olig2 expression (100%)
EGFR ampliﬁed (~40%)
EGFR overexpressed (~60%)
EGFR mutated (~20–30%)
MDM2 ampliﬁed (~10%)
MDM2 overexpressed (>50%)
LOH 10q (~70%)
P16Ink4a/P14ARF loss (~30%)
PTEN mutated (~40%)
PI3K mutated/ampliﬁed (~20%)
RB mutated VEGF overexpressed
Primary Glioblastoma (12-15 
months)
(WHO Grade IV)
Olig2 expression (100%)
P53 mutated (>65%)
PDGFA/PDGFR-α 
overexpressed (~60%)
Low-Grade Astrocytoma (5-10 years)
(WHO Grade II)
LOH 19q (~50%)
RB mutated (~25%)
CDK4 ampliﬁed (15%)
MDM2 overexpressed (10%)
P16Ink4a/P14ARF loss (4%)
LOH 11p (~30%)
Anaplasc Astrocytoma (2–3 
years)*
(WHO Grade III)
LOH 10q (~70%)
DCC loss (~50%) PDGFR-α 
ampliﬁed (~10%)
Anaplasc Oligodendroglioma 
(3–5 yr)* PTEN mutated (~10%)
PI3K mutated/ampliﬁed (~10%)
VEGF overexpressed
Secondary Glioblastoma (12-
15months)
(WHO Grade IV)
Figure 1. Pathways leading to the diagnosis of malignant gliomas. [Figure adapted from (Wen and Kesari 2008)].
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survival rates. A target area for improvement is early diag-
nosis. Patients often attend their GP practice on multiple
occasions (in 2013, 38% of brain tumor patients reported
to their GP more than five times prior to diagnosis) (The
Brain Tumour Charity, 2014), and are then referred for
magnetic resonance imaging (MRI) and/or computed
tomography (CT). These results are then confirmed by
histological assessment of a surgical specimen following a
brain biopsy; however, diagnosis is often made too late for
curative therapy (Bashour et al. 2015; Shanthakumar and
Ganeshkumar 2015). A methodology capable of early diag-
nosis or being able to monitor high-risk patients would
prove to be an extremely valuable tool.
Spectroscopic and spectrometric analysis of biological
samples is regarded as quick, cost effective, easy to oper-
ate and spectroscopic sample preparation involves mini-
mal sample preparation. Techniques like infrared (IR)
spectroscopy, surface-enhanced laser desorption/ioniza-
tion (SELDI)-mass spectroscopy (MS), and matrix-
assisted laser desorption/ionization (MALDI) -MS could
enable early diagnosis of cancer, disease monitoring, and
assessment of treatment responses allowing refinement, if
required. Carrying out analytical testing within outpa-
tient clinics would dramatically cut the time spent by
patients attending different appointments, at different
locations, save hospital time and resources but impor-
tantly would theoretically enable a reduction in mortality
and morbidity (Cancer Research UK). While the advan-
tages of such a prospect seem obvious, this review aims
to evaluate the use of human serum spectroscopic and
spectrometric analysis as a diagnostic tool for brain
cancers, creating a platform for the future of cancer
diagnostics.
Analytical research has focused on identifying a set of
biomarkers indicative of brain cancer that can be identi-
fied during a relatively noninvasive test (Jung et al. 2007;
Kalinina et al. 2011; Marella 2013; Oslobanu and Florian
2015). Blood is a favored sample medium due to the ease
of obtaining samples from patients and highly discrimina-
tory components contained therein. Serum is the liquid
remaining when whole blood is left to clot and then pro-
cessed via a centrifuge, which concentrates the protein
and peptide biomarkers. This short review examines
infrared spectroscopy and mass spectrometry, underlining
recent novel research to understand serum sample
“biosignatures” to profile brain cancer.
Mass Spectrometry
Mass spectrometry (MS) provides information on the
molecular weight of a compound. Samples are ionized
and then fragment in a characteristic manner, allowing
the structure to be determined from a mass spectrum.
SELDI-MS and MALDI-MS are two spectrometry tech-
niques that differ through the way the analyte is captured.
They are the most common variations (Aebersold and
Mann 2003) used for the analysis of biomolecules and
have been used in proteomic profiling for the diagnosis,
prognosis, and therapeutic monitoring of cancer.
The MALDI-MS sample is mixed with an excess
amount of matrix that readily absorbs ultraviolet (UV)
light (Jung et al. 2007) and crystallizes under the influ-
ence of the vacuum. When the matrix is irradiated with
short laser pulses, the ultraviolet light is absorbed causing
the matrix to heat extremely quickly, causing vaporization
of the matrix and the sample (Shimadzu). The analyte is
ionized by charge transfer reactions with the matrix ions.
MALDI is regarded as being extremely useful for the
identification of proteins and peptides. The analyzer usu-
ally coupled to MALDI is a TOF which measures the m/z
ratio of molecules based on the time taken to reach a set
distance (Kalinina et al. 2011). The ions created by the
laser pulse accelerate toward the TOF due to the influence
of an electric field. The potential difference is constant in
relation to all the ions present, meaning either the ions
with the higher charge or the smaller ions reach the
detector first. Knowledge of this, as well as instrumental
constants are used to calculate the m/z.
Despite the sample preparation used in SELDI being
very unique, the technique is regarded as very similar to
MALDI (Issaq 2002). The sample and the matrix are
cocrystallized on the top of a target surface and a laser is
used to ionize the sample. Reports have shown that pro-
tein profiles can be produced from serum samples as
small as one microliter. SELDI-TOF MS has enabled the
discovery of potential diagnostic markers for cancers of
the prostate (Cazares 1999), bladder (Vlahou et al. 2001),
breast (Wulfkuhle 2001; Vlahou 2003), and ovaries
(Petricoin 2002).
The protein chip array is the aspect of the instrumenta-
tion that separates SELDI from all other types of MS.
They are made of chemical or biochemical surfaces that
are designed to specifically retain the proteins of interest.
Often, chemically active surfaces are used to retain whole
groups of proteins, whereas biochemically active surfaces
are used to interact with a single target protein. The
analyzer used is a TOF mass spectrometer as explained
above.
One of the main advantages of SELDI-TOF MS is the
fact that complex samples can be analyzed, making it
particularly useful for the analysis of serum and other
bio-fluids.
There is a large interest in using SELDI-TOF MS to
develop a diagnostic tool for the early detection of dis-
ease. As mentioned above many clinical investigations
have been completed to try and accomplish proteomic
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profiles of different types of cancer, including brain using
SELDI-TOF and bio-fluid samples. This review will go on
to discuss and consolidate such discoveries.
Multiple proof-of-principle studies have been com-
pleted. Zhang et al. (2007) used SELDI-TOF MS to screen
for serum biomarkers of astrocytoma, in which seven
peaks were selected to build a decision tree, able to dis-
criminate cancer from noncancer with sensitivities and
specificities of 84.6% and 86.4%, respectively. Reporting a
higher specificity than MRI, as a result of the inclusion of
low molecular weight compounds not easily detected by
traditional methods, led to Zhang discussing the useful-
ness of SELDI for suspect patients, where MRI findings
were inconclusive (Kalinina et al. 2011). Azok et al.
(2004) discovered four peaks, corresponding to low
molecular weight compounds, in GBM serum samples
that were elevated in comparison to normal patients. This
supported the discussion of contrast-enhanced tumor
regions containing a higher number of low molecular
weight peptides. Liu et al. (2005) screened a total of 22
biomarkers enabling the discrimination of glioma and
benign tumors with sensitivities and specificities of 88.9%
and 86.4%.
Analyzing serum samples using SELDI-TOF MS, with
the aim of screening for specific biomarkers could enable
early detection as well as personalized treatment depen-
dent on the tumor grade (Aebersold and Mann 2003;
Popescu 2010). However, a single parameter enabling the
detection of cancer is highly unlikely (Popescu et al.
2014) and it is thought that a biosignature would be most
efficient due to the heterogeneity of the disease.
MALDI-TOF MS allows the analysis of complicated
sample mixtures with good sensitivities, reporting the
detection of 400 polypeptides within a molecular mass
range of 800–15,000 Da, in a 50 lL drop of serum, estab-
lishing it as a great technique for serum peptide profiling
(Shimadzu). Novel technology was described by Vil-
lanueva et al. (2004) where MALD-TOF MS was used to
simultaneously analyze serum proteins; 1691 peptide
masses were identified over the whole dataset. Refinement
using a Wilcoxon–Mann U-test enabled 274 peptide
masses to be identified, differentiating GBM patients and
controls, correctly classifying 96.4% of predicted samples
as cancerous or not.
Further proof-of-principle research completed a dec-
ade later, 2013, Li et al. (2013) used magnetic beads
to capture peptides within serum. Analysis with MAL-
DI-TOF MS, pattern recognition, and peak intensity
comparisons of 11 peaks were used to classify different
grades of glioma, but concluded that further validation
was needed.
Evidently, several research reports have discussed the
use of SELDI and MALDI to generate peptide profiles of
glioma, with the work discussed being just a few. In
reviewing the reports, peak combinations can be used to
discriminate cancerous samples from noncancerous, but it
can be seen from Table 1 that not all identify the same
peaks. Further validation studies are required and the
search for markers to act as screening tools is ongoing.
The use of vibrational spectroscopy profiles could be
more advantageous to identify cancer from serum sam-
ples, rather than specific, individual serum markers due
to the heterogeneous disease profile of cancer.
IR Spectroscopy
Spectroscopy is the study of molecular structure through
the emission, absorption, or scattering of light and each
of these fundamental processes relate to a different form
of spectroscopy. Spectroscopy can therefore be referred to
as the study of the exchange of energy between electro-
magnetic radiation and matter. Electromagnetic radiation
can be measured as packets of energy called photons
which have specific energies and can be quantized (Smith
and Dent 2005; Larkin 2009).
The sample is scanned using infrared radiation across a
variety of frequencies, allowing many vibrational transi-
tions to occur involving the absorption of light. Each
molecular transition needs a different amount of energy
to do so and create a characteristic signal, allowing the
production of a unique spectrum which acts like a finger-
print of the analyte.
The use of IR spectroscopy in histopathology has been
shown to be successful over the past decade, presenting the
possibility of early diagnosis using less invasive surgical
Table 1. Identified peak combinations from various research projects.
Researcher
No.
identified Peak combination (m/z ratios)
Zhang 7 2018, 4286, 6633, 7567, 8140, 8926, and
15115
Azok 4 2792, 4286, 4503, and 5813
Liu 22 9198.31, 22513.91, 22888.73, 2256.76,
23481.05, 23087.61, 4155.28, 2489.11,
2246.47, 2617.14, 15099.38, 22666.41,
29047.13, 14378.33, 24002.85, 2891.43,
14047.77, 2006.00, 14951.04,2267.22,
23672.58 and 22331.29
Liu 15 8214.77, 8926.76, 4815.11, 8612.23,
2082.19, 4299.87, 2103.54, 7764.82,
2368.19, 3226.97, 2389.55, 2021.78,
4469.09, 6457.054, 8702.416
Villanueva 274 Individual Peaks Not Stated
Li 11 1296.77, 2105.86, 2769.20, 2932.82,
4210.20, 4266.27, 4964.31, 5634.09,
6379.58, 6530.04, 8142.23
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methods and real-time monitoring (Bonnier et al. 2014).
Spectroscopy is a measure of the interaction between light
radiation and matter which is characteristic of the biomole-
cule being examined, allowing the production of a spec-
trum unique to the compound (Larkin 2009).
As with MS, the vast majority of currently published
research involves proof-of-principle studies, highlighting
the many advantages of using Fourier-Transform IR
(FTIR) spectroscopy to differentiate cancerous from non-
cancerous samples. FTIR spectroscopy coupled with data
analysis has been reported to discriminate breast (Backhaus
et al. 2010) and ovarian (Owens et al. 2014) cancers, as
well as grade brain tumors from serum samples.
Gliomas are the most frequently encountered primary
brain tumor in the UK and in 2014 Hands et al. (Azok
et al. 2004) published work using ATR-FTIR spectroscopy
together with support vector machine (SVM) analysis to
discriminate between brain tumors of differing types and
grades. Results demonstrated that the analysis of a 1 lL
drop of serum could produce high quality and reproducible
spectra. The application of SVM analysis enabled analysts
to distinguish between high-grade, low–grade, and non-
cancerous serum samples. Principal component analysis
(PCA) was also used to identify any variance between the
three different serum grades, which were identified as a
result of different protein, lipid, and DNA/RNA peaks.
Whole serum was reported with the greatest specificity and
sensitivity, tentatively assigned to cytokines and chemo-
kines. Hands et al. had previously performed research
demonstrating how cytokines and chemokines could be
used as serum biomarkers to classify serum from glioma
and serum from noncancer patients (Hands et al. 2013).
This was the first time in which biochemical markers and
their characteristic spectrochemical signals were used to
diagnose gliomas from serum samples with sensitivities and
specificities as high as 87.5% and 100%, respectively.
Figure 2. The process from the blood sample being obtained up until the acquired spectrum. Starting with the blood sample taken from the
patient, which is then centrifuged to separate out the serum from all other components. The serum is then analyzed using ATR-FTIR spectroscopy,
which produces a spectrum allowing the protein, lipid, nucleic acid, and carbohydrate peaks to be seen. Data analysis follows which differentiates
cancerous samples from healthy samples. Figure adapted from (Baker et al. 2014).
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Therefore, the diagnosis of gliomas could be achieved
within 10 min of being placed on the ATR-FTIR instru-
mentation.
Infrared analysis is already used worldwide, creating a
mature market for easy translation into routine clinics.
Studies have reviewed the characteristics and advantages
of the technique (Hughes et al. 2016); the proposed
process is highlighted in Figure 2 (Baker et al. 2014).
The minimal sample preparation, the existence of
hand held instrumentation, the simple operation, and
the minimally invasive nature of the technique would
undoubtedly enable analysis of serum samples in a clini-
cal setting (Dorling and Baker 2013). Many of the
research projects discussed have used relatively small
sample populations and results have not progressed
further than the laboratory—a large multi-institutional
study is urgently needed to move this research develop-
ment into clinical practice.
Clinical Translation
Currently the gold standard for the clinical validation of
protein biomarkers are immunoassays such as ELISA, with
MS and IR-based approaches becoming an appealing pro-
spect as a result of the capability at dealing with multiplexed
sample with a high analytical specificity and sensitivity.
However, the multiple advantages of using IR spec-
troscopy within clinics allow future research to involve val-
idation and translation into clinical environments, taking
into consideration all preanalytical factors that could jeop-
ardize approval and limit clinical applications. Hand held
instrumentation would allow spectra to be acquired within
the clinic, significantly decreasing diagnosis time, improv-
ing patient treatment and management, and enable effec-
tive use of healthcare time and resources (Popescu 2010).
Dorling and Baker, presented a schematic highlighting the
potential for serum analysis using spectroscopy within a
clinical environment, expanded further by Hughes et al.
(2016) (Hughes and Baker 2016) – see Figure 3.
There are many sample requirements that must be
taken into account in order to validate a research project.
An appropriate target population of a significant size
must be used, normally with sample sizes increasing, the
closer the discovery gets to being ready for clinics. Robust
statistical analysis of validation data of potential biomark-
ers reduces the chance of bias.
There are current challenges with translating serum
spectroscopic diagnostics to the clinic, demonstrated by
the majority of studies performed involving small-scale
laboratory-based experiments. To enable clinical translation,
studies based on large populations are necessary. Focusing
on procedural and instrumental standardization would
enable regulatory requirements to be met. However, when
moving from the laboratory to large clinical trials, fund-
ing issues and gaining regulatory approval can create a
valley of death which hinders translation of promising
techniques.
Highlighted in Figure 4, is the basic schematic of the
different process leading to the diagnostic test developing
from the laboratory to a clinical environment.
Reports suggest that the most efficient way to achieve
acceptance of work into a clinical environment is to
Figure 3. Schematic showing the potential use of serum spectroscopy within a clinical setting [Figure adapted from (Hughes and Baker 2016)].
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clearly highlight the current unmet needs and the require-
ment for the new clinical and intended uses. Presenting
sufficient evidence in preliminary studies to support the
investment for a large-scale validation study, followed by
the creation of methods with efficient analytical perfor-
mance suitable for use in clinics would allow progression.
Finally, the design and implementation of clinical trials
that allow for the demonstration of clinical usefulness
help the research project to gain regulatory approval. All
steps can be hard to achieve and the involvement of a
multidisciplinary team is essential to ensure the accurate
understanding of each process.
Focusing on the future diagnosis of brain tumors using
spectroscopy and spectrometry methods via minimally inva-
sive procedures, this review highlights the desperate need
for advancement of current methodologies. The advantages
of methods described are clear; quick analysis within a
clinical setting, allowing patients to be treated earlier, and
providing a better chance of survival. However, brain tumor
diagnosis can only be revolutionized by addressing preana-
lytical factors, producing clinical trial plans, government
approval, and understanding the translation into clinics
prior to experimental proof-of-principle studies.
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